Table 4.
Adverse reactions (incidence of at least 10% and at least 2% higher than placebo for dimethyl fumarate) reported in the product labeling for approved oral multiple sclerosis drugs1,3,4a
| Dimethyl fumarate | Placebo | Fingolimod | Placebo |
Teriflunomide |
Placebo | ||
| 7 mg | 14 mg | ||||||
| Abdominal pain | 18% | 10% | |||||
| ALT increased | 14% | 5% | 12% | 14% | 7% | ||
| Alopecia | 10% | 13% | 3% | ||||
| Back pain | 12% | 7% | |||||
| Cough | 10% | 8% | |||||
| Diarrhea | 14% | 11% | 12% | 7% | 15% | 18% | 9% |
| Flushing | 40% | 6% | |||||
| Headache | 25% | 23% | 22% | 19% | 18% | ||
| Influenza | 13% | 10% | 9% | 12% | 10% | ||
| Nausea | 12% | 9% | 9% | 14% | 7% | ||
| Paresthesia | 9% | 10% | 8% | ||||